HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
HAEMONETICS CORP
Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026
$118.73+0.45 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $5.43B
- P/E (TTM)
- 57.9
- Dividend yield
- –
Haemonetics statistics
Financials through Jun 27, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Haemonetics | Industry median |
|---|---|---|
| Market Cap | $5.40B | $229.23M |
| Enterprise Value | $6.35B | $194.73M |
| PE Ratio | 57.92 | 33.41 |
| PS Ratio | 4.00 | 3.14 |
| PB Ratio | 6.45 | 3.19 |
| P/FCF Ratio | 18.55 | 27.25 |
| P/OCF Ratio | 16.46 | 22.23 |
Enterprise value
| Measure | Haemonetics | Industry median |
|---|---|---|
| EV / Sales | 4.70 | 2.93 |
| EV / EBITDA | 23.49 | 19.97 |
| EV / EBIT | 39.62 | 25.47 |
| EV / FCF | 21.81 | 27.85 |
Income (trailing twelve months)
| Measure | Haemonetics | Industry median |
|---|---|---|
| Revenue | $1.35B | $102.39M |
| Gross Profit | $798.15M | $60.36M |
| Operating Income | $160.32M | -$4.31M |
| Pretax Income | $130.44M | -$2.26M |
| Net Income | $96.29M | -$6.57M |
| EBITDA | $270.39M | -$1.98M |
| EPS (Diluted) | $2.05 | -$0.07 |
Margins
| Measure | Haemonetics | Industry median |
|---|---|---|
| Gross Margin | 59.0% | 55.1% |
| Operating Margin | 11.9% | -6.04% |
| Pretax Margin | 9.65% | -4.11% |
| Profit Margin | 7.12% | -10.5% |
| EBITDA Margin | 20.0% | -2.67% |
| FCF Margin | 21.5% | -0.30% |
Returns
| Measure | Haemonetics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 11.2% | -19.2% |
| Return on Assets (ROA) | 3.99% | -13.3% |
| Return on Invested Capital (ROIC) | 6.57% | -4.11% |
| Return on Capital Employed (ROCE) | 7.63% | -9.07% |
Growth
| Measure | Haemonetics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 0.44% | 8.85% |
| Net Income Growth (YoY) | -41.1% | 10.6% |
| EPS Growth (YoY) | -37.3% | 10.6% |
| FCF Growth (YoY) | 53.9% | 10.6% |
| Revenue Growth (3Y CAGR) | 4.51% | 7.08% |
| Revenue Growth (5Y CAGR) | 8.91% | 11.8% |
| EPS Growth (3Y CAGR) | -2.91% | 3.06% |
| EPS Growth (5Y CAGR) | 5.75% | 7.64% |
Balance sheet
| Measure | Haemonetics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $223.38M | $37.33M |
| Total Debt | $1.17B | $72.66M |
| Net Cash (Debt) | -$950.77M | $3.92M |
| Net Cash Per Share | -$20.90 | $0.28 |
| Equity (Book Value) | $837.10M | $57.36M |
| Book Value Per Share | $18.40 | $2.81 |
| Tangible Book Value | -$254.30M | $10.71M |
| Working Capital | $547.60M | $54.64M |
Financial position
| Measure | Haemonetics | Industry median |
|---|---|---|
| Current Ratio | 3.08 | 2.50 |
| Quick Ratio | 1.67 | 1.54 |
| Debt / Equity | 1.40 | 0.38 |
| Debt / EBITDA | 4.34 | 2.31 |
| Debt / FCF | 4.03 | 3.50 |
| Net Debt / EBITDA | 3.52 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Haemonetics | Industry median |
|---|---|---|
| Operating Cash Flow | $328.15M | -$653.46K |
| Capital Expenditures | -$36.93M | -$3.69M |
| Free Cash Flow | $291.22M | -$835.02K |
| FCF Per Share | $6.40 | -$0.02 |
Efficiency
| Measure | Haemonetics | Industry median |
|---|---|---|
| Asset Turnover | 0.56 | 0.59 |
| Inventory Turnover | 1.66 | 2.21 |
Dividends and yields
| Measure | Haemonetics | Industry median |
|---|---|---|
| Earnings Yield | 1.78% | -6.92% |
| FCF Yield | 5.39% | -0.62% |
Shares
| Measure | Haemonetics | Industry median |
|---|---|---|
| Shares Outstanding | 45,497,100 | 44,856,700 |
| Shares Change (YoY) | -6.48% | 3.35% |
| Shares Change (QoQ) | 0.48% | 0.27% |
| Float | 44,697,300 | 36,934,400 |
| Shares Held by Insiders | 1.76% | 10.6% |
| Shares Held by Institutions | 109.1% | 63.5% |
Taxes
| Measure | Haemonetics | Industry median |
|---|---|---|
| Income Tax | $34.15M | $1.52M |
| Effective Tax Rate | 26.2% | 18.6% |
Scores
| Measure | Haemonetics | Industry median |
|---|---|---|
| Graham Number | $29.13 | $34.37 |
| Graham Upside | -75.5% | -58.3% |
| Altman Z-Score | 3.38 | 1.95 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | -2.82 | -2.64 |
Calculated by StockData from Haemonetics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.